Phase 2b clinical trial for Sugardown

Boston Therapeutics (BTHE) initiates a Phase 2b clinical trial to evaluate the safety and effectiveness of its dietary supplement Sugardown. The 24-patient five-week study will assess 4 g and 8 g doses of Sugardown versus placebo on glucose levels in patients with Type 2 diabetes treated with metformin as a monotherapy. The primary endpoint is postprandial serum glucose area under the curve.

Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs